# Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy

Source: https://onco.cc/trials/nct07486687/  
OnCo record `nct07486687` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of pembrolizumab and olaparib in triple-negative breast cancer, run by The Netherlands Cancer Institute, not yet recruiting.

## Summary

Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy is a phase 3, randomised interventional study registered as NCT07486687 by The Netherlands Cancer Institute, with a registry enrolment figure of 1000 participants, started 2026-04 and due to reach its primary completion in 2032-04. Interventions recorded: Standard of care plus pembrolizumab; Standard of care (capecitabine or olaparib). Conditions listed: Triple Negative Breast Cancer (TNBC), Early Setting; Early Stage Triple-Negative Breast Carcinoma; Triple -Negative Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III. Triple-negative eligibility wording from the registry: "Stage II or III TNBC prior to the start of neoadjuvant treatment". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: PLANET
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07486687
- Phase: 3
- Setting: PembroLizumab Adjuvant in Patients With Early-stage Triple NEgaTive Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy - the Multicenter, Randomized Phase III, Pragmatic PLANET Trial
- Sponsor: The Netherlands Cancer Institute
- Enrolled: 1000

## Sources

- ClinicalTrials.gov NCT07486687: https://clinicaltrials.gov/study/NCT07486687

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/)
- drugs: [Olaparib](https://onco.cc/drugs/olaparib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07486687.json